Given the clear importance of IL-1α, IL-1β and IL-33 in lung fibrosis and the likely compensatory action provided by members of the IL-1 cytokine family in vivo, targeting the shared receptors (for example, IL-1RAcP) may be more effective. This evidence concerns the gene IL33 and pulmonary fibrosis.